BDMC-A, an analog of curcumin, inhibits markers of invasion, angiogenesis, and metastasis in breast cancer cells via NF-κB pathway-A comparative study with curcumin

Biomedicine and Pharmacotherapy

Volumn 74, Issue , 2015, Pages 178-186

  Mohankumar, Kumaravel ^a   Sridharan, Subhashree ^a   Pajaniradje, Sankar ^a   Singh, Vivek Kumar ^a   Ronsard, Larance ^b   Banerjea, Akhil C ^b   Somasundaram, Dinesh Babu ^c   Coumar, Mohane Selvaraj ^a   Periyasamy, Latha ^a   Rajagopalan, Rukkumani ^a,c  

^a PONDICHERRY UNIVERSITY   (India)

^b NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^c UNIVERSITY OF MADRAS   (India)

Author keywords

BDMC A; Curcumin; MCF 7; Metastasis; NF B docking; Western blotting

Indexed keywords

BDMC A; CURCUMIN; INTERLEUKIN 1BETA; PROTEIN KINASE P60; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BDMC-A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CELL CULTURE; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; COMPUTER MODEL; DNA BINDING; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MOLECULAR DOCKING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; COMPUTER SIMULATION; DRUG EFFECTS; METABOLISM; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PREVENTION AND CONTROL; VASCULARIZATION;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; COMPUTER SIMULATION; CURCUMIN; FEMALE; HUMANS; MCF-7 CELLS; MOLECULAR DOCKING SIMULATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84940861862     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.07.024     Document Type: Article

References (58)

1. Wang N., Ren D., Deng S., Yang X. Differential effects of baicalein and its sulfated derivatives in inhibiting proliferation of human breast cancer MCF-7 cells. Chem. Biol. Interact. 2014, 221C:99-108.
2. Sanjit B. Breast cancer rises in India. Can. Med. Assoc. J. 2008, 179:27.
3. Sharon McGee F. Understanding metastasis: current paradigms and therapeutic challenges in breast cancer progression. RCSI smj. Rev. 2010, 3:56-60.
4. Duffy M.J. Inhibiting tissue invasion and metastasis as targets for cancer therapy. Biotherapy 1992, 4:45-52.
5. Kohn E.C., Liotta L.A. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995, 55:1856-1862.
6. Jayanarayanan S., Smijin S., Peeyush K.T., Anju T.R., Paulose C.S. NMDA and AMPA receptor mediated excitotoxicity in cerebral cortex of streptozotocin induced diabetic rat:ameliorating effects of curcumin. Chem. Biol. Interact. 2013, 201:39-48.
7. Derochette S., Franck T., Mouithys-Mickalad A., Deby-Dupont G., Neven P., Serteyn D. Intra- and extracellular antioxidant capacities of the new water-soluble form of curcumin (NDS27) on stimulated neutrophils and HL-60 cells. Chem. Biol. Interact. 2013, 201:49-57.
8. Devipriya B., Kumaradhas P. Molecular flexibility and the electrostatic moments of curcumin and its derivatives in the active site of p300: atheoretical charge density study. Chem. Biol. Interact. 2013, 204:153-165.
9. Hasima N., Aggarwal B.B. Cancer-linked targets modulated by curcumin. Int. J. Biochem. Mol. Bio. 2012, 3:328-351.
10. Gupta S.C., Kim J.H., Prasad S., Aggarwal B.B. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 2010, 29:405-434.
11. Anand P., Sundaram C., Jhurani S., Kunnumakkara A.B., Aggarwal B.B. Curcumin and cancer: an old-age disease with an age-old solution. Cancer Lett. 2008, 267:133-164.
12. Kamat A.M., Sethi G., Aggarwal B.B. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol. Cancer Ther. 2007, 6:1022-1030.
13. Divya C.S., Pillai M.R. Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NF-κB and AP-1 translocation, and modulation of apoptosis. Mol. Carcinog. 2006, 45:320-332.
14. Li L., Aggarwal B.B., Shishodia S., Abbruzzese J., Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004, 101:2351-2362.
15. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5:297-309.
16. Yang C.H., Yue J., Sims M., Pfeffer L.M. The curcumin analog EF24 targets NF-kappaB and miRNA-21, and has potent anticancer activity in vitro and in vivo. PloS One 2013, 8:e71130.
17. Hahm E.R., Gho Y.S., Park S., Park C., Kim K.W., Yang C.H. Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis. Biochem. Biophys. Res. Commun. 2004, 321:337-344.
18. Anto R.J., George J., Babu K.V., Rajasekharan K.N., Kuttan R. Antimutagenic and anti carcinogenic activity of natural and synthetic curcuminoid. Mutat. Res. 1996, 370:127-131.
19. Anto R.J., Kuttan G., Babu K.V.D., Rajasekharan K.V., Kuttan R. Anti-tumour and free radical scavenging activity of synthetic curcuminoids. Int. J. Pharm. 1996, 131:1-7.
20. Rukkumani R., Aruna K., Varma P.S., Rajasekaran K.N., Menon V.P. Comparative effects of curcumin and an analog of curcumin on alcohol and PUFA induced oxidative stress. J. Pharm. Pharm. Sci. 2004, 7:274-283.
21. Rukkumani R., Aruna K., Varma P.S., Viswanathan P., Rajasekaran K.N., Menon V.P. Protective role of a novel curcuminoid on alcohol and PUFA-induced hyperlipidemia. Toxicol. Mech. Methods 2005, 15:227-234.
22. Rajagopalan R., Sridharana S., Menon V.P. Hepatoprotective role of bis-demethoxy curcumin analog on the expression of matrix metalloproteinase induced by alcohol and polyunsaturated fatty acid in rats. Toxicol. Mech. Methods 2010, 20:252-259.
23. Devasena T., Rajasekaran K.N., Menon V.P. Bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione (a curcumin analog) ameliorates DMH-induced hepatic oxidative stress during colon carcinogenesis. Pharmacol. Res. 2002, 46:39-45.
24. Kumaravel M., Sankar P., Rukkumani R. Antiproliferative effect of an analog of curcumin bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione in human breast cancer cells. Eur. Rev. Med. Pharmacol. Sci. 2012, 16:1900-1907.
25. Mohankumar K., Pajaniradje S., Sridharan S., Singh V.K., Ronsard L., Banerjea A.C., Benson C.S., Coumar M.S., Rajagopalan R. Mechanism of apoptotic induction in human breast cancer cell, MCF-7, by an analog of curcumin in comparison with curcumin-an in vitro and in silico approach. Chem. Biol. Interact. 2014, 210:51-63.
26. Singh S., Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med. Chem. 2006, 6:259-270.
27. Sarada S., Himadri P., Mishra C., Geetali P., Ram M.S., Ilavazhagan G. Role of oxidative stress and NF-κB in hypoxia-induced pulmonary edema. Exp. Biol. Med. 2008, 233:1088-1098.
28. Dinesh Babu K.V., Rajasekharan K.N. Simplified conditions for the synthesis of curcumin I and other curcuminoids. Org. Prep. Proced. Int. 1994, 24:674-677.
29. Fido R.J., Tatham A.S., Shewry P.R. Western blotting analysis. Methods in Molecular Biology: Plant Gene Transfer and Expression Protocols 1995, 49:423-437. Humana Press. 1st edition.
30. Gupta S.C., Sundaram C., Reuter S., Aggarwal B.B. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim. Biophys. Acta. 2010, 1799:775-787.
31. Tafani M., Pucci B., Russo A., Schito L., Pellegrini L., Perrone G.A., Villanova L., Salvatori L., Ravenna L., Petrangeli E., Russo M.A. Modulators of HIF1α and NFkB in cancer treatment: is it a rational approach for controlling malignant progression?. Front. Pharmacol. 2013, 4:13.
32. Metelev V., Zhang S., Tabatadze D., Bogdanov A. Hairpin-like fluorescent probe for imaging of NF-κB transcription factor activity. Bioconjug. Chem. 2011, 22:759-765.
33. Chung S.S., Vadgama J.V. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NF-κBsignaling. Anticancer Res. 2015, 35:39-46.
34. Al-Halabi R., Bou Chedid M., Abou Merhi R., El-Hajj H., Zahr H., Schneider-Stock R., Bazarbachi A., Gali-Muhtasib H. Gallotannin inhibits NFκB signaling and growth of human colon cancer xenografts. Cancer Biol. Ther. 2011, 12:59-68.
35. Chien W., Lee D.H., Zheng Y., Wuensche P., Alvarez R., Wen D.L., Aribi A.M., Thean S.M., Doan N.B., Said J.W., Koeffler H.P. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Mol. Carcinog. 2014, 53:722-735.
36. Li Q., Verma I.M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2002, 2:725-734.
37. Dehm S.M., Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem. Cell Biol. 2004, 82:263-274.
38. Biscardi J.S., Belsches A.P., Parsons S.J. Characterization of human epidermal growth factor receptor and src interactions in human breast tumor cells. Mol. Carcinog. 1998, 21:261-272.
39. Mohankumar K., Pajaniradje S., Sridharan S., Singh V.K., Ronsard L., Banerjea A.C., Benson C.S., Coumar M.S., Periyasamy L., Rajagopalan R. Apoptosis induction by an analog of curcumin (BDMC-A) in human laryngeal carcinoma cells through intrinsic and extrinsic pathways. Cell. Oncol. 2014, 37:439-454. 10.1007/s13402-014-0207-3.
40. Simeone A.M., Nieves-Alicea R., McMurtry V.C., Colella S., Krahe R., Tari A.M. Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells. Int. J. Oncol. 2007, 30:785-792.
41. Singh B., Berry J.A., Shoher A., Ramakrishnan V., Lucci A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int. J. Oncol. 2005, 26:1393-1399.
42. Ristimaki A., Sivula A., Lundin J., Lundin M., Salminen T., Haglund C., Joensuu H., Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62:632-635.
43. Kim E.H., Na H.K., Kim D.H., Park S.A., Kim H.N., Song N.Y., Surh Y.J. 15-Deoxy-Delta12,14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS. Carcinogenesis 2008, 29:688-695.
44. Price J.T., Thompson E.W. Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin. Ther. Targets 2002, 6:217-233.
45. Boissan M., De Wever O., Lizarraga F., Wendum D., Poincloux R., Chignard N., Desbois-Mouthon C., Dufour S., Nawrocki-Raby B., Birembaut P., Bracke M., Chavrier P., Gespach C., Lacombe M.L. Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res. 2010, 70:7710-7722.
46. Lin S.S., Lai K.C., Hsu S.C., Yang J.S., Kuo C.L., Lin J.P., Ma Y.S., Wu C.C., Chung J.G. Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Lett. 2009, 285:127-133.
47. Papathoma A.S., Petraki C., Grigorakis A., Papakonstantinou H., Karavana V., Stefanakis S., Sotsiou F., Pintzas A. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res. 2000, 20:2009-2013.
48. Bourboulia D., Stetler-Stevenson W.G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin. Cancer Biol. 2010, 20:161-168.
49. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219.
50. Katsuno Y., Lamouille S., Derynck R. TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr. Opin. Oncol. 2013, 25:76-84.
51. Freund A., Chauveau C., Brouillet J.P., Lucas A., Lacroix M., Licznar A., Vignon F., Lazennec G. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003, 22:256-265.
52. Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2009, 85:314-323.
53. Mosaffa F., Lage H., Afshari J.T., Behravan J. Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflamm. Res. 2009, 58:669-676.
54. Kumar A., Bora U. In silico inhibition studies of NF-κB p50 subunit by curcumin and its natural derivatives. Med. Chem. Res. 2012, 21:3281-3287.
55. Venkata M., Sripathy R., Anjana D., Somashekara N., Krishnaraju A., Krishanu S., Murali M., Rama Verma S., Ramchand C.N. In Silico, in vitro and in vivo assessment of safety and anti-inflammatory activity of curcumin. Am. J. Infect. Dis. 2012, 8:26-33.
56. Han S.S., Keum Y.S., Seo H.J., Surh Y.J. Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J. Biochem. Mol. Biol. 2002, 35:337-342.
57. Zhang C., Li B., Zhang X., Hazarika P., Aggarwal B.B., Duvic M. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling. J. Invest. Dermatol. 2010, 130:2110-2119.
58. Prasad S., Ravindran J., Aggarwal B.B. NF-kappaB and cancer: how intimate is this relationship. Mol. Cell Biochem. 2010, 336:25-37.